The Hospital

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Itch, Medication, Alagille syndrome, Liver disease, Inflammation, Patient, Cholestasis, Bile, Cholestatic pruritus, CADTH, Liver injury, The Hospital, Liver, CDEC, Genetic disorder, PFIC, Pharmaceutical industry

“The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.

Key Points: 
  • “The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.
  • These patients suffer greatly from the debilitating and disruptive effects of Alagille syndrome, which often starts in early childhood.”
    “CADTH’s recommendation of reimbursement for LIVMARLI provides a meaningful advancement in the treatment of cholestatic pruritus for patients with Alagille syndrome.
  • LIVMARLI is also approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. and Europe, and for Progressive Familial Intrahepatic Cholestasis (PFIC) in the U.S. and in Europe.
  • Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.

Aspect Imaging Celebrates First Installation of Embrace® Neonatal MRI System in Canada at The Hospital for Sick Children in Toronto

Retrieved on: 
Thursday, March 28, 2024
Medical Devices, Health, Hospitals, Health Technology, Clinical Trials, General Health, The Hospital, NICU, Patient, MRI, Environment, Medical imaging

Aspect Imaging, the leading provider of compact MRI solutions, is proud to announce the successful installation of the Embrace® Neonatal MRI System at The Hospital for Sick Children (SickKids) in Toronto, Ontario, marking a significant milestone as the first installation of its kind in Canada.

Key Points: 
  • Aspect Imaging, the leading provider of compact MRI solutions, is proud to announce the successful installation of the Embrace® Neonatal MRI System at The Hospital for Sick Children (SickKids) in Toronto, Ontario, marking a significant milestone as the first installation of its kind in Canada.
  • The Embrace® Neonatal MRI System, renowned for its compact design and advanced patient-focused approach to MRI, is specifically tailored to meet the unique needs of premature and newborn patients within the environment of the neonatal intensive care unit (NICU).
  • "We are thrilled to be bringing the Embrace® Neonatal MRI System to Canada," said Wendy Slatery, Chief Commercial Officer of Aspect Imaging.
  • The addition of the Embrace® Neonatal MRI System joins the hospital's comprehensive suite of diagnostic tools, helping clinicians to care for some of their youngest patients.

Radiant to Assess Multi-Valent, Multi-Specific Multabodies as Potential Treatments for HIV

Retrieved on: 
Wednesday, December 20, 2023
Biotechnology, AIDS, Health, Consumer, Pharmaceutical, Professional Services, Philanthropy, Research, Infectious Diseases, Start-Up, LGBTQ+, Foundation, Science, Cardiology, Associate, University, Disease, Infection, Radiant, HIV, Cell, Bill, Patient, Memory, Therapy, The Hospital, Vaccine

The agreement includes a commitment to three potential infectious disease targets which includes the HIV funding and interest in a potential equity investment in the company.

Key Points: 
  • The agreement includes a commitment to three potential infectious disease targets which includes the HIV funding and interest in a potential equity investment in the company.
  • The funding supports a two year-long project, which enables Radiant to evaluate the Multabody™ platform’s ability to destroy latent stores of the HIV virus, along with its ability to eliminate circulating viral particles.
  • “Our Multabody™ platform potentially addresses a shortcoming of existing antiviral treatments for HIV,” said Arthur J. Fratamico, President and Chief Executive Officer of Radiant Biotherapeutics.
  • “HIV is a challenging virus that constantly mutates and escapes immune responses and suboptimal treatments.

Dr. LIANG Xiao of SRRSH Invited as ELSA 2023 Sole Keynote Speaker from Mainland China

Retrieved on: 
Wednesday, October 11, 2023
Congress, General surgery, CAI, Health care, Medicine, Cai, Endoscopy, Sir Run Run Shaw Hospital, University of the Chinese Academy of Sciences, Government, Hepatocellular carcinoma, Zhejiang University School of Medicine, The Hospital, Robotics, Hospital, Chinese Academy of Medical Sciences COVID-19 vaccine, Trauma, Speech, Assistant, SRRSH, Minimally invasive procedure, China Association for Science and Technology, Research, Science, Medical device, Dentistry

Dr. LIANG Xiao delivered a speech titled "New Era of Minimally Invasive Surgery for Hepatocellular Carcinoma in China", sharing the latest and significant technological advancements in minimally invasive surgery with the audience.

Key Points: 
  • Dr. LIANG Xiao delivered a speech titled "New Era of Minimally Invasive Surgery for Hepatocellular Carcinoma in China", sharing the latest and significant technological advancements in minimally invasive surgery with the audience.
  • With great enthusiasm, Dr. LIANG introduced SRRSH, which is dedicated to promoting and applying minimally invasive surgical techniques.
  • The Hospital is one of the leading institutions in China with the broadest range of minimally invasive surgical procedures and involvement in various disciplines.
  • With Dr. CAI Xiujun, the President of SRRSH, leading the way, the Hospital has progressed steadily, achieving remarkable results.

Dr. Doria A. Scortichini MD, FACC Joins Auburn Heart Institute

Retrieved on: 
Wednesday, July 19, 2023
Workforce, Auburn Hospital, Jacobi Medical Center, Auburn Community Hospital, Primary care, ACH, Multimedia, Cardiology, Finger Lakes, Drug, University of Ottawa Heart Institute, National Association Medical Staff Services, Medical director, Patient, Investment, The Hospital, Physician, MD, Internal medicine, Tertiary referral hospital, Hospital, Union University, Montreal Heart Institute, Lake, Medical device

AUBURN, N.Y., July 19, 2023 /PRNewswire/ -- Dr. Doria Scortichini, MD FACC joins the growing Auburn Heart Institute that is affiliated with Auburn Community Hospital.  Dr. Scortichini is a cardiology specialist in Geneva, New York and has over 40 years of experience in cardiovascular diseases.  Dr. Scortichini graduated from Albany Medical College of Union University and completed her residency and cardiology fellowship at Bronx Municipal Hospital and Albert Einstein College of Medicine Hospital followed by a fellowship in interventional cardiology at the Montreal Heart Institute. Dr. Scortichini is board certified in Internal Medicine and Cardiovascular Diseases.

Key Points: 
  • AUBURN, N.Y., July 19, 2023 /PRNewswire/ -- Dr. Doria Scortichini, MD FACC joins the growing Auburn Heart Institute that is affiliated with Auburn Community Hospital.
  • "We are thrilled to have someone of Dr. Scortichini' s experience join the Auburn Heart Institute and Auburn Community Hospital.
  • "I am excited to join the team at the Auburn Heart Institute, and to be part of Auburn Hospital and this community.
  • Patients can begin scheduling appointments immediately to be seen by Dr. Scortichini at the Auburn Heart Institute 3rd Floor Auburn Community Hospital  - Please call:  315-567-0540 for appointments.

Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice

Retrieved on: 
Tuesday, June 27, 2023
NICU, LARS, Lactation, Imperial College London, Survival, University of California, San Diego, Quality, Science, Mother, Milk, University, Hospital, Great Western Hospital, Infant, Great Western Hospitals NHS Foundation Trust, AU, Pediatrics, Late preterm infant, Physiology, Research, Obstetrics, Knowledge, European Association of Urology, British Association of Perinatal Medicine, Initiation, Neonatology, Social support, Government, Translation, OMM, Standard of care, The Hospital, Nursing credentials and certifications, University of Pennsylvania School of Nursing, Medicine, Family, Breast milk, Partnership, Woman, Health, Qi, Nursing, Dairy, Birth control

Switzerland, Baar, June 27, 2023 (GLOBE NEWSWIRE) -- Medela, the brand trusted by millions of moms*, concluded its 16th Global Breastfeeding and Lactation Symposium, focused on advancing lactation science to improve care.

Key Points: 
  • Switzerland, Baar, June 27, 2023 (GLOBE NEWSWIRE) -- Medela, the brand trusted by millions of moms*, concluded its 16th Global Breastfeeding and Lactation Symposium, focused on advancing lactation science to improve care.
  • “By bringing together top minds in lactation science from around the world, we are able to further our shared goal of improving maternal and infant health outcomes,” said Annette Brüls, CEO of  Medela worldwide.
  • “Medela’s Symposium brings new lactation evidence to clinician leaders who will translate the science to the bedside for families around the world.
  • On day two of the symposium the healthcare experts on-site took these findings into curated workshops with the goal of translating them into clinical practice.

Bionano Announces 2023 Winners of its Innovator Research Grant Program

Retrieved on: 
Monday, June 12, 2023
Hospital for Sick Children, Lymphoma, Duke University, Research Triangle, Central nervous system, ALL, Acute lymphoblastic leukemia, Cutaneous T-cell lymphoma, Stanford University, CTCL, Genomics, Pathology, Cancer, SVS, Prognosis, Research, Infection, Biomarker, Doctor of Philosophy, CNS, Creativity, Drug resistance, Patient, The Hospital, SAN, Neoplasm, Hospital, Health, OGM, DSM-IV codes, Bone marrow, Medical imaging, Vaccine, Pharmaceutical industry

Additionally, 12 other winners from around the world have been awarded complimentary OGM services from Bionano Laboratories.

Key Points: 
  • Additionally, 12 other winners from around the world have been awarded complimentary OGM services from Bionano Laboratories.
  • Bionano’s Innovator Research program was established to fuel novel research using the company’s OGM products to detect relevant structural variants (SVs), demonstrating OGM’s potential to advance discoveries and innovation in ways that may elevate health and wellness for all people.
  • The Bionano Innovator Research Grant will enable us to resolve structural variants as they arise during treatment and to determine their role in drug resistance.
  • The Bionano Innovator Research Grant program was established to attract applicants with projects that demonstrate exemplary vision and creativity in leveraging OGM and genomic technologies to tackle complex challenges.

The Highlight of The Hamptons’ Season: Stony Brook Southampton Hospital Annual Summer Party Returns!

Retrieved on: 
Monday, June 5, 2023
Dance, Life, Sagaponack, New York, Single person, Hospital, The Hospital, Hamptons (magazine), Trauma center, Sound, American College, Lighting, Table, Engineer Research and Development Center, Splenic infarction, Healthgrades, Research, British Hospitality Association, Photography, Colony Hotel, Corporation, Stony Brook Southampton Hospital, St. Supéry Estate Vineyards & Winery, Chairperson, Emergency department, Audrey, Wickapogue Road Historic District, Joint Commission, Publicity, Partnership, Sheila, Just Dance: Summer Party, Colony, Purism, American Colony Hotel, Stony Brook University Hospital, Jenny, BC Children's Hospital Foundation, Tourism, Hotel, Drinking establishment, Furniture, The Hamptons

“Stony Brook Southampton Hospital is a pillar of its community, much like The Colony Hotel.

Key Points: 
  • “Stony Brook Southampton Hospital is a pillar of its community, much like The Colony Hotel.
  • "Wölffer is proud to be the wine sponsor for this year’s Summer Party, to continue to support all the great work Stony Brook Southampton Hospital does for our community," Joey expressed.
  • Stony Brook Southampton Hospital is the only hospital on the South Fork.
  • As part of Stony Brook University Hospital, Stony Brook Southampton Hospital also shares in this recognition.

Brain Cancer Canada Matches Community Fundraising to Support Groundbreaking DIPG Research

Retrieved on: 
Wednesday, May 17, 2023
Hospital for Sick Children, Survivor, Therapy, Friends, Parent, Rafal E. Dunin-Borkowski, Clinical trial, Hope, Traffic barrier, Research, High-intensity focused ultrasound, Borkowski, Patient, The Hospital, BCC, Partnership, Brain, Diffuse intrinsic pontine glioma, Caregiver, Medical imaging, DIPG

Dr. Rutka’s research project targets childhood Diffuse Intrinsic Pontine Glioma (DIPG), a highly aggressive tumour that currently has no effective treatments.

Key Points: 
  • Dr. Rutka’s research project targets childhood Diffuse Intrinsic Pontine Glioma (DIPG), a highly aggressive tumour that currently has no effective treatments.
  • The grant starts with an incredible $50,000 raised by the tireless DIPG community, an amount matched by BCC to support this critical research further.
  • "From a broader perspective, DIPG also has one of the highest societal burdens of any disease.”
    Dr. Rutka's early-stage research proposes a novel approach to addressing DIPG.
  • This research grant embodies the tenacity and hope of the DIPG community.

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

Retrieved on: 
Monday, May 8, 2023
LEPR, Hospital for Sick Children, Faculty, University of Alberta, Benzyl alcohol, Priority review, Obesity, Depression, University, Weight loss, Bardet–Biedl syndrome, Pigment, POMC, BBS, Very early onset inflammatory bowel disease, Arousal, Publication, Patient, PCSK1, The Hospital, Medicine, Hypothalamus, Nausea, Suicidal ideation, University of Melbourne Faculty of Medicine, Dentistry and Health Sciences, Health Canada, Hunger, Human, Skin, Pharmaceutical industry, Nursing, Endocrinology, MC4R

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company, today announced that Health Canada has approved IMCIVREE® (setmelanotide solution for subcutaneous injection) for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS) or genetically-confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance. Please consult the IMCIVREE product monograph available at www.rhythmtx.ca.

Key Points: 
  • Setmelanotide has been shown to reduce the weight of patients living with BBS or POMC, PCSK1 or LEPR deficiency.
  • The trials met all primary endpoints and key secondary endpoints among patients at 52 weeks on therapy.
  • Results from these trials were featured in several publications, including the peer-reviewed journal The Lancet Diabetes and Endocrinology .
  • The most common adverse reactions were skin hyperpigmentation, injection site reactions and nausea.